Semaglutide acts on three key mechanisms: 1) It affects GLP-1 receptors in the hypothalamus (hunger and satiety center), reducing appetite and the desire to eat; 2) It slows gastric emptying (gastroparesis), allowing the feeling of fullness to persist for 4–6 hours after eating; 3) It stimulates insulin secretion and lowers glucagon levels, improving glucose metabolism. According to the STEP-1 clinical trial, published in the New England Journal of Medicine (NEJM) in February 2021, participants on the 2.4 mg dose lost an average of 14.9% of body weight over 68 weeks.

For type 2 diabetes (Ozempic): starting dose — 0.25 mg subcutaneously once weekly for 4 weeks (GI adaptation period). Then increase to 0.5 mg per week. If needed — up to 1 mg, maximum — 2 mg per week. For weight management (Wegovy): 0.25 mg (weeks 1–4) → 0.5 mg (weeks 5–8) → 1 mg (weeks 9–12) → 1.7 mg (weeks 13–16) → 2.4 mg (from week 17, maintenance dose). Each step — minimum 4 weeks. Gradual escalation minimizes GI side effects. A DOZA specialist selects the regimen individually.

According to FDA data, the most common side effects of semaglutide: nausea — 15.8–20.3% (mainly during dose escalation), diarrhea — 8.5–8.8%, vomiting — 5–9.2% (more common at 1 mg), abdominal pain — 5.7–7.3%, constipation — 3.1–5%. Most symptoms are mild, temporary, and resolve within the first weeks of adaptation. Only 3.1–3.8% of patients discontinued treatment due to GI effects (vs 0.4% on placebo). Serious side effects are rare: pancreatitis (<0.3%), cholecystitis (1.2%). Contraindications: medullary thyroid cancer, MEN-2 syndrome, pregnancy. A DOZA specialist supports the entire adaptation process — any discomfort is managed by adjusting the protocol.

The main difference is in the mechanism of action. Ozempic (semaglutide) acts only on GLP-1 receptors, while Mounjaro (tirzepatide, Eli Lilly) is a dual agonist of GLP-1 and GIP receptors. According to clinical data: Mounjaro provides up to -22.5% weight loss over 72 weeks (SURMOUNT-1, NEJM 2022), Ozempic — up to -14.9% over 68 weeks (STEP-1, NEJM 2021). Mounjaro is approximately 50% more effective. Both products are administered subcutaneously once weekly. The side effect profile is similar (predominantly GI). Detailed comparison — on the Mounjaro vs Ozempic page.

Yes, original Ozempic from Novo Nordisk is available in Ukraine through DOZA. The program includes a specialist consultation and cold-chain delivery at 2-8°C. A trial dose is also available — try one injection before starting the program. The global shortage (since August 2022) limits supply, but DOZA maintains availability. See current pricing on the Ozempic — program pricing page. Ozempic dosing catalog.

Ozempic is administered subcutaneously once weekly using a FlexTouch pen injector. The injection can be given on any day of the week, at any time of day — regardless of meals. It is recommended to choose a fixed day (e.g., Monday) for convenience. Injection sites: abdomen, thigh, or upper arm. The injection takes 5–10 seconds, the needle is very thin — most patients barely feel any pain.

No strict diet is needed. Semaglutide naturally reduces appetite through its action on GLP-1 receptors in the hypothalamus — you will start eating less without willpower. However, balanced nutrition and moderate physical activity significantly improve effectiveness. In the STEP-1 study, all participants followed a reduced-calorie diet (-500 kcal from needs) and did 150 minutes of physical activity per week. A DOZA specialist will provide individual dietary recommendations.

Ozempic and Wegovy are two brands from the same manufacturer (Novo Nordisk) containing the same active ingredient — semaglutide. The difference: Ozempic (doses 0.25, 0.5, 1, 2 mg) was approved by the FDA in 2017 for type 2 diabetes. Wegovy (doses up to 2.4 mg) was approved by the FDA in June 2021 specifically for chronic weight management. The maximum Wegovy dose (2.4 mg) is higher — and this is the dose that produced STEP-1 results (-14.9% weight loss). The mechanism of action is identical, the difference is in indications and maximum dose.

According to STEP-1 extension data, after discontinuing semaglutide, participants regained approximately 2/3 of lost weight over the following year. This confirms that obesity is a chronic condition requiring a long-term approach. However, the STEP-5 study showed: with 2 years of continuous use, the -15.2% effect is maintained stably (104 weeks). The DOZA program includes building new eating habits and a gradual tapering protocol for maximum result preservation.

The rate of weight loss depends on dosing and individual characteristics. According to STEP-1: first 4 weeks (0.25 mg, adaptation) — 1–3 kg; over 3 months — 5–8% of starting weight; over 6 months — 10–13%; over 68 weeks — average 14.9%. For a person weighing 100 kg this is approximately: 2–3 kg in the first month, 7–10 kg over 3 months, 12–15 kg over 6 months. Results depend on following specialist recommendations and starting weight.

Ozempic/Wegovy is suitable for adults (18+) with BMI ≥30 (obesity) or BMI ≥27 with comorbidities (type 2 diabetes, hypertension, dyslipidemia). Contraindications: medullary thyroid cancer (or MTC in family history), MEN-2 syndrome (multiple endocrine neoplasia type 2), pregnancy and breastfeeding, severe GI disorders (acute pancreatitis), allergy to semaglutide or product components. A specialist consultation is required before starting — DOZA provides it free of charge.

STEP-1 (Semaglutide Treatment Effect in People with obesity) is a landmark randomized double-blind placebo-controlled trial published in NEJM (New England Journal of Medicine) in February 2021. 1,961 adult participants with obesity (without diabetes) received semaglutide 2.4 mg/week or placebo for 68 weeks. Results: mean weight loss -14.9% (semaglutide) vs -2.4% (placebo); 86.4% of participants lost ≥5% of weight; 69.1% — ≥10%; 50.5% — ≥15%. In absolute numbers: -15.3 kg vs -2.6 kg. Side effects: GI symptoms — predominantly mild and temporary.

According to clinical data: 1) Diets without medication: average weight loss 3–5% (often returns within a year); 2) Orlistat tablets (Xenical): -2.9–3.4% per year; 3) Ozempic/Wegovy 2.4 mg: -14.9% over 68 weeks (STEP-1); 4) Mounjaro (tirzepatide) 15 mg: -22.5% over 72 weeks (SURMOUNT-1). GLP-1 agonists show 3–5 times higher efficacy than pills. The reason — they act directly on hunger centers in the brain, rather than simply blocking fat absorption.

The STEP-5 study (Nature Medicine, 2022) confirmed the safety and efficacy of semaglutide 2.4 mg over 104 weeks (2 years). The SELECT Trial (NEJM, 2023) — the largest study (17,604 participants, 39.8 months) — showed that semaglutide reduces the risk of cardiovascular events (heart attack, stroke, cardiovascular death) by 20%. In March 2024, the FDA approved Wegovy for reducing cardiovascular risk. This is the first GLP-1 agonist with proven cardioprotective effect.

Before first use: store in a refrigerator at 2–8°C. Do not freeze. After first use: the FlexTouch pen can be stored at room temperature (up to 30°C) or in the refrigerator for 56 days (8 weeks). After 56 days — dispose of it, even if product remains. DOZA delivers Ozempic in thermal boxes with cold packs to maintain the 2–8°C cold chain during transport.

Step 1: Check the product — the liquid should be clear, colorless or slightly yellowish, with no particles. Step 2: Attach a new NovoFine needle (included in the kit). Step 3: Set the required dose on the pen counter. Step 4: Insert the needle subcutaneously at 90° into the abdomen, thigh, or upper arm. Step 5: Press the button and hold for 6 seconds. Step 6: Remove the needle. Rotate injection sites weekly. The procedure takes less than a minute.

It is not recommended to combine semaglutide with other GLP-1 agonists (e.g., liraglutide). With insulin — possible, but insulin dose adjustment is needed (risk of hypoglycemia). With metformin — the combination is safe and commonly used for type 2 diabetes. With oral contraceptives — semaglutide may slow their absorption due to delayed gastric emptying. However, Amylin (Cagrilintide) — the only amylin hormone analog that acts through a pathway separate from GLP-1 and combines well with Ozempic: in the CagriSema study (semaglutide + cagrilintide), -22.7% weight loss was achieved over 68 weeks. Order Amylin in Ukraine to enhance the Ozempic effect. Any combination with other products requires specialist consultation.

If less than 5 days have passed: inject as soon as possible, then continue on your regular schedule. If 5+ days have passed: skip this dose and take the next one on schedule. Do not inject a double dose to compensate for the missed one. If 2+ doses in a row are missed, contact a specialist — schedule adjustment may be needed. A DOZA specialist is available 24/7 on Telegram for any questions about the dosing schedule.

Semaglutide is contraindicated during pregnancy and breastfeeding. It is recommended to discontinue at least 2 months before a planned pregnancy (semaglutide elimination period — 5 weeks). Data on effects on human fertility are limited. In preclinical animal studies, high doses of semaglutide affected embryonic development. Women of reproductive age are advised to use contraception during treatment.

Both products from Novo Nordisk contain semaglutide but in different forms: Ozempic — an injection once weekly (doses 0.25–2 mg), Rybelsus — a daily tablet (3, 7, or 14 mg). The injectable form is more effective for weight loss (in the PIONEER 4 study: the 14 mg tablet showed -5% vs the 1 mg injection -7.6%). The tablet must be taken on an empty stomach 30 minutes before food with no more than 120 ml of water. The injection is more convenient (once a week, regardless of food).